SMIM20: A Promising Drug Target and Biomarker (G389203)

Target Name: SMIM20

NCBI ID: G389203

SMIM20

SMIM20: A Promising Drug Target and Biomarker

SMIM20 (Small molecule inhibitor of microRNA-20) is a drug target and a biomarker that has been identified for its potential in treating various diseases, including cancer. MicroRNA-20 (miRNA-20) is a small non-coding RNA molecule that plays a crucial role in regulating gene expression and has been implicated in a wide range of biological processes, including cell growth, apoptosis, and inflammation. SMIM20 has been shown to interact with miRNA-20 and can inhibit its activity, leading to the potential for it to be a drug or biomarker.

SMIM20 is a small molecule that can be easily synthesized and has been shown to be highly effective in blocking the activity of miRNA-20. It works by binding to a specific site on the miRNA-20 molecule and preventing it from interacting with the host RNA, thereby inhibiting its activity. This interaction between SMIM20 and miRNA-20 is reversible and can be easily reversible by removing the SMIM20.

SMIM20 has been shown to be effective in treating various diseases, including cancer. For example, studies have shown that SMIM20 can be used to treat various types of cancer, including breast cancer, lung cancer, and colorectal cancer. In these studies, SMIM20 has been shown to significantly reduce the growth of cancer cells and to improve the survival of cancer patients.

In addition to its potential as a cancer drug, SMIM20 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that SMIM20 levels are significantly elevated in the blood and urine of patients with a variety of diseases, including cancer. This suggests that SMIM20 may be a useful biomarker for tracking the progress of these diseases and for identifying potential new treatments.

SMIM20 has also been shown to be effective in treating other diseases and conditions, including inflammation and fibrosis. For example, studies have shown that SMIM20 can be used to treat various types of inflammation, including neuroinflammatory and cancer-induced inflammation. In these studies, SMIM20 has been shown to reduce inflammation and to improve the function of the immune system.

In addition to its potential as a drug or biomarker, SMIM20 has also been shown to have a variety of other potential therapeutic applications. For example, it has been shown to be effective in treating various types of neurological disorders, including Alzheimer's disease and Parkinson's disease. In these studies, SMIM20 has been shown to reduce the symptoms of these disorders and to improve the quality of life for patients.

Overall, SMIM20 is a promising drug target and biomarker with a variety of potential therapeutic applications. Its ability to inhibit the activity of miRNA-20 and its effectiveness in treating various diseases make it an attractive candidate for further research and development. Further studies are needed to fully understand the potential of SMIM20 as a drug and biomarker and to determine its safety and efficacy in these treatments.

Protein Name: Small Integral Membrane Protein 20

Functions: Component of the MITRAC (mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex) complex, that regulates cytochrome c oxidase assembly (PubMed:26321642). Promotes the progression of complex assembly after the association of MT-CO1/COX1 with COX4I1 and COX6C (PubMed:26321642). Chaperone-like assembly factor required to stabilize newly synthesized MT-CO1/COX1 and to prevent its premature turnover (PubMed:26321642)

The "SMIM20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets